Growth Metrics

Armata Pharmaceuticals, Inc. (ARMP) EBIT (2016 - 2018)

Armata Pharmaceuticals' EBIT history spans 6 years, with the latest figure at -$2.8 million for Q4 2018.

  • For Q4 2018, EBIT fell 18.14% year-over-year to -$2.8 million; the TTM value through Dec 2018 reached -$17.4 million, down 8.0%, while the annual FY2024 figure was -$42.4 million, 3.78% down from the prior year.
  • EBIT for Q4 2018 was -$2.8 million at Armata Pharmaceuticals, up from -$8.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$746000.0 in Q3 2017 and bottomed at -$16.1 million in Q4 2016.
  • The 5-year median for EBIT is -$2.9 million (2018), against an average of -$4.4 million.
  • The largest annual shift saw EBIT skyrocketed 85.3% in 2017 before it plummeted 1073.86% in 2018.
  • A 5-year view of EBIT shows it stood at -$2.6 million in 2014, then rose by 6.51% to -$2.4 million in 2015, then plummeted by 562.73% to -$16.1 million in 2016, then surged by 85.3% to -$2.4 million in 2017, then fell by 18.14% to -$2.8 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's EBIT are -$2.8 million (Q4 2018), -$8.8 million (Q3 2018), and -$2.8 million (Q2 2018).